Biotech grants in France
Explore Biotech grants for companies in France. This list brings together funding for drug discovery, diagnostics, cell and gene therapy, biomanufacturing and life-science research from French innovation agencies, research funders and foundations, EU and international programs open to applicants in France, and competitions any company can enter, with the deadline, award size and eligibility on every listing. Grants aimed at Biotech in France come first.
Showing 241-264 of 637 grants
Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research
NIH · United States
Funds the development and hard technical validation that turns a working cancer research technology into one other laboratories will actually adopt.
Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research
NIH · United States
Funds proof-of-concept work on a genuinely new tool, assay, platform or instrument for characterising cancer cells or handling biospecimens.
Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21)
NIH · United States
Funds the same reanalysis of already-collected cancer data on a smaller, exploratory footing, for teams that do not need a full research project award.
Ethical, Legal and Social Implications (ELSI) Exploratory/Developmental Research Grant
NIH · United States
Funds exploratory studies of the ethical, legal and social consequences of human genetics, especially where a technology or a use of genomic data is new.
Ethical, Legal and Social Implications (ELSI) Research
NIH · United States
Funds a full research project on the ethics, law and social effects of human genetics — and refuses to review an application with no diverse-perspectives plan.
Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD)
NIH · United States
Funds one bundled run from first-in-human through phase 2a for a dementia drug that works on something other than amyloid or tau.
Developing novel theory and methods for understanding the genetic architecture of complex human traits (R21)
NIH · United States
Funds the exploratory version of the same theory-and-methods work on complex trait variation, for ideas that need testing before a larger project is justified.
Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01)
NIH · United States
Funds work on how GLP-1 and related drugs change cancer risk — raising it for some cancers, lowering it for others.
Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21)
NIH · United States
Funds smaller, higher-risk work on how GLP-1 and related drugs change cancer risk. No clinical trial in this version.
National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis
NIH · United States
Funds a Phase 0, I or II cancer trial that the investigator designed, inside one of six named National Cancer Institute programme areas.
NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders
NIH · United States
Funds Phase I trials for heart, lung, blood and sleep disorders — and pays for the final preclinical work needed to start one.
Minor Use Minor Species Development of Drugs
FDA · United States
Funds the safety and effectiveness testing costs of getting a designated new animal drug through FDA approval.
BRAIN Initiative: Development and Validation of Novel Tools to Probe Cell-Specific and Circuit-Specific Processes in the Brain
NIH · United States
Funds new genetic or non-genetic tools that deliver genes, proteins or chemicals to specific brain cells or circuits, with validation built in.
Development and Validation of Novel Tools to Probe Cell-Specific and Circuit-Specific Processes in the Brain
BRAIN Initiative · United States
Funds new methods to study brain cells and circuits with tools for deeper neural research.
NIDA Animal Genomics Program
NIH · United States
Funds genomic work in animals on what makes addiction start, escalate, persist and relapse — any kind of genetic variant.
Accelerating Discovery through Partnered Research with All of Us to Analyze Participant Biospecimens
NIH · United States
Funds running new assays on stored blood, serum and DNA from the All of Us Research Program's biobank.
Discovery of in vivo Chemical Probes for the Nervous System
NIH · United States
Funds optimizing an already-validated hit compound into an in vivo chemical probe for a novel brain target.
High Priority HIV and Substance Use Research (R01)
NIH · United States
Funds research where HIV and drug use intersect. Preliminary data are compulsory, and the work must sit on NIH's published HIV priorities.
Opportunities for Collaborative Research at the NIH Clinical Center
NIH · United States
Funds a translational research project run jointly with NIH's own intramural investigators at the Clinical Center, up to $500,000.
Cutting-Edge Basic Research Awards (CEBRA)
NIH · United States
Funds high-risk addiction research that is sparse or absent from the institute's current portfolio — a revolutionary method, or a hypothesis with no precedent.
Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System
NIH · United States
Funds a biologic for a nervous system disorder from lead optimisation to phase I, with NIH-paid manufacturing and tox work — and the applicant keeps the IP.
Investigator Initiated Innovation in Computational Genomics and Data Science (R01)
NIH · United States
Funds computational genomics work — new analytical methods, early-stage tools, or hardening software the genomics community already relies on.
Investigator Initiated Innovation in Computational Genomics and Data Science (R21)
NIH · United States
Funds the exploratory version of the same computational genomics work — new methods, early tools, or hardening software the field depends on.
Integrating Biospecimen Science Approaches into Clinical Assay Development
NIH · United States
Funds research into how preanalytical handling of biopsies and other biospecimens distorts biomarker results used in clinical assays.